Name: ALUMIS INC (ALMS) Stock
Brand: ALUMIS INC
Rating: 7 (3 reviews)

ALMS Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Chartmill - Mentions: WHLR SPWH DOMO PSN ...

What's going on in today's session

11 days ago - By: Chartmill - Mentions: IRBT WHLR SPWH DOMO ...

Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session.

a month ago - By: Benzinga - Mentions: CCOI JHX GSM FOXF ...

Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday

a month ago - By: Alumis Inc.

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

a month ago - By: Alumis Inc.

Alumis to Participate in Upcoming November Investor Conferences

2 months ago - By: Benzinga - Mentions: EXEL CCM CLLS GMAB ...

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

4 months ago - By: Alumis Inc.

Alumis to Participate in Upcoming September Investor Conferences

4 months ago - By: The Motley Fool

Alumis Misses Q2 Revenue as Costs Jump

4 months ago - By: Alumis Inc.

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Yahoo Finance - Mentions: SLRN

Alumis (ALMS) Merges with ACELYRIN

5 months ago - By: Alumis Inc.

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

5 months ago - By: Alumis Inc.

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

7 months ago - By: Alumis Inc.

Alumis to Present at the Jefferies Global Healthcare Investor Conference

7 months ago - By: Alumis Inc.

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

7 months ago - By: Alumis Inc.

Alumis Completes Merger with ACELYRIN

7 months ago - By: ACELYRIN, INC. - Mentions: SLRN

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

7 months ago - By: Alumis Inc.

Alumis Stockholders Approve Merger with ACELYRIN

7 months ago - By: ACELYRIN, INC. - Mentions: SLRN

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

8 months ago - By: Yahoo Finance - Mentions: WGS LB CEP SLRN ...

Why Investors Were Avoiding GeneDx Holdings Stock This Week

8 months ago - By: Yahoo Finance - Mentions: SLRN DHI CMG SBUX

Acelyrin urges stockholders to vote for proposed merger with Alumis

8 months ago - By: ACELYRIN, INC. - Mentions: SLRN

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

8 months ago - By: Yahoo Finance - Mentions: SLRN MA DHI CMG ...

Acelyrin should liquidate instead of merging with Alumis, investor says

8 months ago - By: ACELYRIN, INC. - Mentions: SLRN

ALUMIS INC (ALMS) Stock News

ALMS Latest News, Press Relases and Analysis

What's going on in today's session

Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session.

Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis to Participate in Upcoming November Investor Conferences

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Alumis to Participate in Upcoming September Investor Conferences

Alumis Misses Q2 Revenue as Costs Jump

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis (ALMS) Merges with ACELYRIN

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Stockholders Approve Merger with ACELYRIN

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

Why Investors Were Avoiding GeneDx Holdings Stock This Week

Acelyrin urges stockholders to vote for proposed merger with Alumis

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Acelyrin should liquidate instead of merging with Alumis, investor says

Alumis and ACELYRIN Announce Amended Merger Agreement